Kardigan Completes KATALYST-AV Trial Enrollment in AS
Health
Business Update
IPO:
Jun 18, 2026
Industry:
PHARMACEUTICAL PREPARATIONS
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence in Aortic Stenosis
SOUTH SAN FRANCISCO, Calif., and PRINCETON, N.J., USA - Kardigan, Inc. (Nasdaq: KARD), a precision cardiovascular company, has completed patient enrollment in its Phase 2b KATALYST-AV trial evaluating ataciguat in people with aortic stenosis (AS). Alongside this milestone, the company shared new insights from a pre-planned baseline analysis and a large real-world study involving approximately 45,000 patients, supporting an updated trial timeline and primary endpoint assessment at Week 48.
... Read on — Members only
About Kardigan, Inc.
Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Our mission is to develop multiple targeted cardiovascular treatments in parallel that bring people with cardiovascular diseases closer to the cures they deserve. We leverage deep domain expertise in cardiovascular biology, patient data, and advanced analytics to accelerate drug discovery and development, aiming to deliver impactful therapies efficiently and at scale.
